[113mIn]In-PSMA: high potential agent for SPECT imaging of prostate cancer

IF 1.4 3区化学 Q4 CHEMISTRY, INORGANIC & NUCLEAR

Radiochimica Acta Pub Date : 2024-09-03 DOI:10.1515/ract-2024-0298

Leyla Akbari, Sedigheh Sina, Samaneh Zolghadri, Ali Moghaddasi, Kamal Hadad, Hassan Yousefnia

{"title":"[113mIn]In-PSMA: high potential agent for SPECT imaging of prostate cancer","authors":"Leyla Akbari, Sedigheh Sina, Samaneh Zolghadri, Ali Moghaddasi, Kamal Hadad, Hassan Yousefnia","doi":"10.1515/ract-2024-0298","DOIUrl":null,"url":null,"abstract":"The prevalence rate of prostate cancer is very high and unfortunately causes many deaths worldwide. This study aimed to prepare [113mIn]In-PSMA as a novel agent for single photon emission computed tomography (SPECT) imaging of prostate cancer. 113mIn was eluted from an in-house made 113Sn/113mIn generator in chloride form, and its radionuclide, chemical and radiochemical purities was studied. [113mIn]In-PSMA was prepared with radiochemical purity (RCP) > 99 % under optimal labeling conditions. The biodistribution of the labeled compound was studied in normal rats, showed the major activity in the urine and kidneys as the main excretion route from the body. Considerable uptake was observed in the prostate and salivary glands as the PSMA-expressing organs. These data are in complete agreement with the other published data on PSMA-labeled compounds both in animals and humans. The results demonstrated [113mIn]In-PSMA can be considered as a good option for SPECT imaging of prostate cancer.","PeriodicalId":21167,"journal":{"name":"Radiochimica Acta","volume":"47 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiochimica Acta","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1515/ract-2024-0298","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

The prevalence rate of prostate cancer is very high and unfortunately causes many deaths worldwide. This study aimed to prepare [113mIn]In-PSMA as a novel agent for single photon emission computed tomography (SPECT) imaging of prostate cancer. 113mIn was eluted from an in-house made 113Sn/113mIn generator in chloride form, and its radionuclide, chemical and radiochemical purities was studied. [113mIn]In-PSMA was prepared with radiochemical purity (RCP) > 99 % under optimal labeling conditions. The biodistribution of the labeled compound was studied in normal rats, showed the major activity in the urine and kidneys as the main excretion route from the body. Considerable uptake was observed in the prostate and salivary glands as the PSMA-expressing organs. These data are in complete agreement with the other published data on PSMA-labeled compounds both in animals and humans. The results demonstrated [113mIn]In-PSMA can be considered as a good option for SPECT imaging of prostate cancer.

查看原文本刊更多论文

[113mIn]In-PSMA：用于前列腺癌 SPECT 成像的高潜力制剂

前列腺癌的发病率非常高，不幸的是，它在全球范围内造成了许多人死亡。本研究旨在制备[113mIn]In-PSMA，作为前列腺癌单光子发射计算机断层扫描（SPECT）成像的新型制剂。113mIn 以氯化物形式从自制的 113Sn/113mIn 发生器中洗脱出来，研究了其放射性核素、化学纯度和放射化学纯度。在最佳标记条件下制备的[113mIn]In-PSMA的放射化学纯度（RCP）为99%。在正常大鼠体内对标记化合物的生物分布进行了研究，结果表明该化合物主要在尿液中活动，肾脏是其排出体外的主要途径。在前列腺和唾液腺等 PSMA 表达器官中也观察到了大量吸收。这些数据与其他已发表的 PSMA 标记化合物在动物和人体中的数据完全一致。结果表明，[113mIn]In-PSMA 可被视为前列腺癌 SPECT 成像的良好选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Radiochimica Acta 化学-核科学技术

CiteScore

2.90

自引率

16.70%

发文量

审稿时长

6 months

期刊介绍： Radiochimica Acta publishes manuscripts encompassing chemical aspects of nuclear science and technology.